EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
February 29 2024 - 7:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company
committed to developing and commercializing therapeutics to improve
the lives of patients with serious retinal diseases, today
announced it will host a conference call and live webcast at 8:30
a.m. ET on Thursday, March 7, 2024 to report its fourth quarter and
full-year 2023 financial results and highlight recent corporate
developments.
To access the live conference call, please
register using the audio conference link:
https://register.vevent.com/register/BI91be5d0e320646e887cf4047c70fe73c.
A live audio webcast of the event can be accessed via the Investors
section of the Company website at www.eyepointpharma.com. A webcast
replay will also be available on the corporate website at the
conclusion of the call.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
clinical-stage biopharmaceutical company committed to developing
and commercializing therapeutics to help improve the lives of
patients with serious retinal diseases. The Company's pipeline
leverages its proprietary bioerodible Durasert E™ technology for
sustained intraocular drug delivery. The Company’s lead product
candidate, EYP-1901, is an investigational sustained delivery
treatment for VEGF-mediated retinal diseases combining vorolanib, a
selective and patent-protected tyrosine kinase inhibitor with
Durasert E™. Pipeline programs include EYP-2301, a promising TIE-2
agonist, razuprotafib, f/k/a AKB-9778, formulated in Durasert E™ to
potentially improve outcomes in serious retinal diseases. The
proven Durasert® drug delivery technology has been safely
administered to thousands of patient eyes across four U.S. FDA
approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by
Equinox Sciences, a Betta Pharmaceuticals affiliate, for the
localized treatment of all ophthalmic diseases outside of China,
Macao, Hong Kong and Taiwan.
Investors:Christina
TartagliaStern IRDirect:
(212)-698-8700christina.tartaglia@sternir.com
Media ContactAmy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024
